BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

AcroMetrix Announces Launch of First Liquid MRSA Positive Control


3/25/2008 10:41:51 AM

Benicia, CA, March 25, 2008 - AcroMetrix, a leading provider of quality control products and services for clinical diagnostic laboratories, announced today the launch of the first standardized External Quality Control for Methicillin Resistant Staphylococcus aureas (MRSA) molecular testing. The OptiQual MRSA Positive Control may be used to independently monitor all phases of MRSA DNA testing to ensure consistent and accurate results.

A study published October 2007 in the Journal of the American Medical Association estimated that MRSA infections resulted in the death of 18,650 out of 94,360 infected patients in the United States in 2005 – a death rate higher than that of HIV/AIDS in the same year. Since then, many efforts have been highlighted to urge state and federal lawmakers to enact a bill requiring all incoming hospital patients be screened for MRSA upon being admitted.

The costs involved when MRSA spreads through a hospital are staggering. The VA Medical Center of Pittsburgh estimated in September 2007 that nearly $35,000 is spent per patient in treatment for MRSA. In addition, the website for the Center for Medicare and Medicaid services states that CMS is analyzing the need to adjust reimbursements for hospital-acquired infections such as MRSA.

“With the urgency currently associated with the MRSA screening, it is critical that hospitals are able to implement screening tests with the appropriate level of quality control,” said Michael J. Eck, President and CEO of AcroMetrix. “Many critical and costly treatment decisions will be based on the results of these tests so it is important for patients that the tests are properly monitored during all phases of the testing procedure.”

Each lab can help to maintain CLIA compliance for qualitative PCR tests such as those used to detect MRSA DNA by using the OptiQual MRSA Positive Control daily. These controls contain inactivated whole MRSA bacteria, providing a safer method of monitoring the entire PCR process, from extraction through amplification and detection. Convenient and ready to use, the OptiQual MRSA Positive Control is stored at refrigerated temperatures. This product is for Research Use Only. Not for use in diagnostic procedures.

OptiQual® is a registered trademark of AcroMetrix.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES